Presentation is loading. Please wait.

Presentation is loading. Please wait.

The core pillars and thematic hallmarks of anti-tumour immunity governing response to immune checkpoint blockade Figure 2 from Cogdill et al. British.

Published byStéphanie Leblanc Modified over 5 years ago

Similar presentations

Presentation on theme: "The core pillars and thematic hallmarks of anti-tumour immunity governing response to immune checkpoint blockade Figure 2 from Cogdill et al. British."— Presentation transcript:

1 The core pillars and thematic hallmarks of anti-tumour immunity governing response to immune checkpoint blockade Figure 2 from Cogdill et al. British Journal of Cancer Advance Online Publication 18 May 2017 doi: /bjc Several approaches exist to target Eph receptors. Kinase inactivating strategies include kinase inhibitors or blocking peptides or antibodies. Kinase activating strategies include ligand stimulation, activating antibodies or ligand peptide mimetics Strategies to deliver toxic payloads following receptor activation and internalisation include coupling of cytotoxic agents or radionuclides to Eph monoclonal antibodies. © 2017 The Author(s).

Download ppt "The core pillars and thematic hallmarks of anti-tumour immunity governing response to immune checkpoint blockade Figure 2 from Cogdill et al. British."

Similar presentations

Advanced Cancer Topics Journal Review 4/16/2009 AD.

Advanced Cancer Topics Journal Review 4/16/2009 AD.
Overview of Targeted Therapy Mechanisms November 11, 2011 Targeted Therapies and Biological Therapies SIG.

Overview of Targeted Therapy Mechanisms November 11, 2011 Targeted Therapies and Biological Therapies SIG.
Schema for a human microbiome study

Schema for a human microbiome study
Pembrolizumab Drugbank ID :DB09037 Half life : 28 days.

Pembrolizumab Drugbank ID :DB09037 Half life : 28 days.
Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors  Sara Charmsaz, Andrew M. Scott,

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors  Sara Charmsaz, Andrew M. Scott,
Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints
Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4 antibodies. Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4.

Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4 antibodies. Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4.
Figure 7 Clinical options for HCC therapy

Figure 7 Clinical options for HCC therapy
Focus on breast cancer Cancer Cell

Focus on breast cancer Cancer Cell
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
The PI3K/Akt signalling and its activation in cancer

The PI3K/Akt signalling and its activation in cancer
The hallmarks of adenovirus infection

The hallmarks of adenovirus infection
The cellular immune response to cancer is complex and involves a diverse repertoire of immunoregulatory interactions principally involving antigen presenting.

The cellular immune response to cancer is complex and involves a diverse repertoire of immunoregulatory interactions principally involving antigen presenting.
Schematic diagram of antibody drug conjugate

Schematic diagram of antibody drug conjugate
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 Co-stimulatory receptors as immunomodulatory targets

Figure 2 Co-stimulatory receptors as immunomodulatory targets
Figure 4 Combination immunotherapeutic approaches with imatinib

Figure 4 Combination immunotherapeutic approaches with imatinib
Figure 6 Combination therapy for HCC

Figure 6 Combination therapy for HCC
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol
Figure 4 Macrophage-targeting antitumour treatment approaches

Figure 4 Macrophage-targeting antitumour treatment approaches

Similar presentations

Ads by Google